Clinical trial NCT01261052: Real-time Adaptation to Changes in Insulin Sensitivity
Official title: Sensor-Controlled Insulin and Glucagon Delivery in Subjects With Type 1 Diabetes: Real-time Adaptation to Changes in Insulin Sensitivity
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Type 1 Diabetes Mellitus
Keywords: glucose sensors
artificial pancreas
Diabetes Mellitus
Lead sponsor: Legacy Health System
Sponsor class: OTHER
Collaborators: name: Juvenile Diabetes Research Foundation
First posted: 2010-12-16
Enrollment: 14
Sex: ALL
Minimum age (years): 21
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The purpose of this research study is to test an automated blood glucose control system that includes a new component designed to adapt to stress. The importance of this component is that when Type 1 Diabetics are stressed (for example, from illness or infection), their body is resistant to the effects of insulin. The investigators will be adjusting their blood glucose using insulin and glucagon and making their body less sensitive to insulin with a steroid, hydrocortisone. Insulin is a hormone that lowers blood glucose. Glucagon raises blood glucose when it is low. Both are natural hormones made by people without diabetes. Hydrocortisone is a steroid that will increase their blood glucose temporarily and will be given every 4 hours. All subjects will participate in two 33 hour experiments. One experiment will use the adaptive version of the sensor-based glucose control system. The other study will use the original version of the control system, without the adaptive component, for the first 13 hours. Then, the adaptive component will be added to the glucose control system for the remaining 20 hours of the study. Our primary goal is to assess the effectiveness of the adaptive component to control glucose levels in the presence of steroid-induced insulin resistance in persons with Type 1 Diabetes Mellitus.


Eligibility criteria: Inclusion Criteria:

* Diagnosis of Type 1 Diabetes Mellitus for at least 1 year
* Male or Female subjects 21 to 65 years of age
* Willingness to follow all study procedures, including attending all clinic visits
* Willingness to sign informed consent and HIPAA documents.

Exclusion Criteria:

* Pregnancy or Lactation: For women of childbearing potential: there is a requirement for a negative urine pregnancy test and for agreement to use contraception during the study and for at least 1 month after participating in the study. Acceptable contraception includes birth control pill / patch / vaginal ring, Depo-Provera, Norplant, an IUD, the double barrier method (the woman uses a diaphragm and spermicide and the man uses a condom), or abstinence.
* Renal insufficiency (serum creatinine of 2.0 mg/dL or greater).
* Serum ALT or AST equal to or greater than 3 times the upper limit of normal; hepatic synthetic insufficiency as defined as a serum albumin of less than 3.3 g/dL; or serum bilirubin of over 2.
* Adrenal insufficiency
* Hematocrit of less than or equal to 34%.
* A history of cerebrovascular disease or coronary artery disease regardless of the time since occurrence.
* Congestive heart failure, NYHA class III or IV.
* Cardiac rhythm disturbance characterized by: 2nd or 3rd degree heart block, bradycardia of less than 50 bpm (exception of bradycardia in an aerobic athlete), tachycardia of greater than 100 bpm, or any arrhythmia judged by the investigator to be exclusionary.
* Any active infection.
* Visual impairment preventing reading of glucose meter values or continuous glucose monitoring device.
* Physical impairment impeding the ability to use a glucose meter or glucose monitoring device.
* Active foot ulceration.
* Severe peripheral arterial disease characterized by ischemic rest pain or severe claudication.
* Active alcohol abuse, substance abuse, or severe mental illness (as judged by the principal investigator).
* Active malignancy, except basal cell or squamous cell skin cancers.
* Major surgical operation within 30 days prior to screening.
* Seizure disorder.
* Any concurrent illness, other than diabetes, that is not controlled by a stable therapeutic regimen.
* Chronic usage of any immunosuppressive medication (such as cyclosporine, azathioprine, sirolimus, or tacrolimus).
* Current administration of oral or parenteral corticosteroids.
* Use of an investigational drug within 30 days prior to screening.
* Bleeding disorder, treatment with warfarin, or platelet count below 50,000.
* History of major non-compliance.
* Allergy to aspart insulin.
* Allergy to glucagon.
* Past history of pheochromocytoma or a family history of MEN 2, neurofibromatosis, or von Hippel-Lindau disease.
* Insulin resistance requiring more than 200 units per day.
* Need for uninterrupted treatment of acetaminophen.
* Intolerance of mild hypoglycemia (glucose 60-70 mg/dl).
* Patients using all dietary supplements (except for vitamin supplements, calcium or vitamin D in standard doses).
* Patients with a history of glaucoma or who have not had an ophthalmologic exam in the previous 2 years (because of the risk of increased intraocular pressure)
* Patients with a history of psychiatric disease or steroid-induced psychosis.
* Patients currently on estrogen supplementation (low dose estrogen contraceptives are not exclusionary).
* Chronic use of dietary supplements that contain adrenal cell extracts, adrenal cortical extracts, or other hormones.
* The use of dietary supplements (except for vitamin supplements, calcium or vitamin D in standard doses) will be exclusionary (unless the subjects agrees to abstain from taking such supplements for three weeks before beginning the study.
* Administration of an immunization (such as a flu or travel immunization) or plans to receive such an immunization within one week of beginning of the study.
* Any reason the principal investigator deems exclusionary.

Primary outcomes:
measure: Measurement of the Effectiveness of APD and FMPD/APD Intervention in Adapting to Reduced Insulin Sensitivity
timeFrame: all 33 hour studies
Secondary outcomes:
measure: Measurement of APD and FMPD/APD Interventions in Controlling Post-prandial Blood Glucose With Reduced Insulin Sensitivity.
timeFrame: all 33 hour studies
Other outcomes:
Locations:
city: Portland
country: United States
facility: Legacy Good Samaritan Hospital
state: Oregon
Study officials:
affiliation: Legacy Health Research
name: W K Ward, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Castle JR, Engle JM, El Youssef J, Massoud RG, Yuen KC, Kagan R, Ward WK. Novel use of glucagon in a closed-loop system for prevention of hypoglycemia in type 1 diabetes. Diabetes Care. 2010 Jun;33(6):1282-7. doi: 10.2337/dc09-2254. Epub 2010 Mar 23.